NCT07025551View on ClinicalTrials.gov

A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015)

PHASE1RecruitingINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

September 19, 2025

Primary Completion Date

December 8, 2025

Study Completion Date

January 7, 2026

Conditions

Hepatic ImpairmentHealthy Participants

Interventions

DRUG

MK-8527

Oral administration

Trial Locations (1)

85225

RECRUITING

Arizona Clinical Trials ( Site 0001), Chandler

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY